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Momordica charantia extracts protect against
inhibition of endothelial angiogenesis by advanced
glycation endproducts in vitro
Ali Aljohi,†a Sabine Matou-Nasri,†b Donghui Liu,a Nadia Al-Khafaji,a Mark Slevina and
Nessar Ahmed *a
Diabetes mellitus characterized by hyperglycemia favors formation of advanced glycation endproducts
(AGEs) capable of triggering vascular complications by interfering with imbalanced inﬂammation and
angiogenesis to eventually impede wound-healing. Momordica charantia (MC, bitter melon) has been
shown to prevent AGE formation and to promote angiogenesis in diabetic wounds in animal models.
However, the mechanism underlying its eﬀects on angiogenesis is unclear. We investigated the eﬀects of
methanolic extracts of MC pulp (MCP), ﬂesh (MCF) and charantin (active component of MC) using an
in vitro model of angiogenesis. MC extracts or low concentrations of bovine serum albumin-derived AGEs
(BSA-AGEs) stimulated proliferation, migration (using wound-healing assay) and tube formation (using
Matrigel™-embedded 3D culture) of bovine aortic endothelial cells (BAEC) together with increases in the
phosphorylation of extracellular signal-regulated kinase (ERK)1/2, the key angiogenic signaling cyto-
plasmic protein. Blocking the receptor for AGEs (RAGE) inhibited low BSA-AGE- and MC extract-induced
ERK1/2 phosphorylation and tube formation, indicating the crucial role of RAGE in the pro-angiogenic
eﬀects of MC extracts. Moreover, inhibitory eﬀects of high BSA-AGE concentration on cell proliferation
and migration were reduced by the addition of MC extracts, which reversed the BSA-AGE anti-angiogenic
eﬀect on tube formation. Thus, MC extracts exert direct pro-angiogenic signaling mediated via RAGE to
overcome the anti-angiogenic eﬀects of high BSA-AGEs, highlighting the biphasic RAGE-dependent
mechanisms involved. This study enhances our understanding of the mechanisms underlying the pro-
angiogenic eﬀects of MC extracts in improvement of diabetes-impaired wound-healing.
1 Introduction
Diabetes is a chronic metabolic disease characterized by hyper-
glycemia. It is a major public health problem and now con-
sidered as the fourth most common cause of death in most
developed countries.1 Hyperglycemia favors the formation of
advanced glycation endproducts (AGEs) as a result of glycation
of plasma proteins such as albumin, extracellular matrix pro-
teins such as collagen, lipids or even of nucleic acids like
DNA.2,3 Increased AGE formation occurs in the kidneys, skin
and vascular tissues.4–6 High concentration of AGEs aﬀect
tissues and cause various adverse cellular events, including
increased free radical activity, which can damage cell mem-
branes and promote mutations, alterations in enzymatic
activity, cross-linking and impaired degradation of proteins.7,8
These biochemical and cellular disturbances lead to the onset
of diabetes-related vascular complications.9,10
These vascular complications result from an imbalanced
inflammation and from the dysregulation of angiogenesis,
defined as the formation of new blood vessels from pre-exist-
ent ones. The micro-environment aﬀects the outcome of angio-
genic responses in patients with diabetes mellitus. For
instance, in the retina, hypervascularization can occur (dia-
betic retinopathy), whereas in other tissues, including diabetic
foot ulcers, significant delays and impaired healing of both
acute and chronic wounds are observed.11,12 Many studies
have described both pro- and anti-angiogenic eﬀects of AGEs,
with eﬀects that vary with the concentrations and types of
AGEs.13,14 These dose-dependent eﬀects mainly involve inter-
action with the receptor for AGEs (RAGE), a 45 kDa transmem-
brane multi-ligand receptor belonging to the immunoglobulin
superfamily, with the ability to transduce a bell-shaped curve
cell response indicating a bivalent bridging mechanism.15†These authors equally contributed to the work.
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This bivalent mechanism is explained on the one hand by the
induction of the cell response after dimerization/oligomeriza-
tion of the receptor facilitated by a low ligand concentration
and, on the other hand; by the loss/inhibition of the cell
response due to the impediment of the receptor oligomeriza-
tion at high ligand concentrations.15 Ligation of RAGE leads to
activation of phosphorylated extracellular signal-regulated
kinase (p-ERK)-1/2, the key angiogenic signaling protein.16–18
Momordica Charantia Linn (MC) is a member of the
Cucurbitaceae family and is also known as bitter melon, bitter
gourd, balsam pear in English or Karela in Hindi. Its fruit is
eaten in many Asian countries including Pakistan, India,
Nepal, China, and in tropical Africa.19 MC primarily consists
of glycosides, proteins, saponins, reducing sugars, sterols,
fatty acids and volatile constituents,20 and contains biologi-
cally active chemicals such as charantins (mixtures of steroidal
saponins also called momocharins), insulin-like peptides
(called ‘polypeptide-P’), and alkaloids with hypoglycemic
eﬀects (e.g. momordicin presents in seed) and ascorbigens,
bound forms of ascorbic acid.20,21 Charantin is a non-nitrogen-
ous neutral mixture of steroidal saponins, composed of sitos-
teryl glucoside and stigmasteryl glucoside.20 The fruit pulp,
the leaf juice and the seeds of MC have been consumed as
dietary supplements and used in ethno-medicine for
centuries22–24 for their hypolipidemic, antioxidant,25 contra-
ceptive,26 and anti-bacterial properties.27 The products of this
plant have been shown to have anti-inflammatory,28 anti-
cancer,29 anti-ulcerogenic activities30 and wound-healing31
activities.
Recently, many studies have reported beneficial eﬀects of
MC extracts on wound-healing.32–34 Using normal rats and rats
with diabetes induced by streptozotocin, it has been shown
that the administration of dried MC extracts improved and
accelerated the process of healing in wounded skin.32 This
eﬀect was accompanied by a significant increase in the protein
content of the skin in the MC extract-treated diabetic group
compared with the untreated diabetic group, suggesting that
MC extracts may stimulate cell proliferation through an
unknown mechanism.32 An extract of the leaves of MC (in
benzene and 95% ethanol) significantly increased the rates of
wound closure and epithelialization compared with untreated
animals.33 Topical application of an olive oil extract of MC to
wounded rabbit skin or the topical application of aqueous
extract of seed and outer layer of MC onto full-thickness skin
wounds in albino rats also promoted wound-healing.31,34
Recently using a wound chamber model in rats, local appli-
cation of MC extracts has been reported to promote granula-
tion tissue growth and angiogenesis in the diabetic wound.35
However, the molecular mechanisms involved in the pro-
angiogenic eﬀects of MC extracts and charantin have not yet
been described.
Here, we demonstrate that MC extracts and charantin
promote angiogenesis in vitro using endothelial cell prolifer-
ation, migration, tube formation and phosphorylation of
ERK1/2 through RAGE. We also showed that these MC extracts
and charantin reduced the anti-angiogenic eﬀects of high con-
centration of AGEs using cell proliferation and wound-healing
assays, while it was reversed using tube formation assay.
This investigation could help us improve our understanding
of the wound-healing capacity of these substances in diabetic
patients in order to enhance their beneficial eﬀects for the pre-
vention of diabetic vascular complications.
2 Materials and methods
2.1 Preparation of Momordica charantia (MC) extracts
and charantin
Extracts of the outer layer (the flesh, MCF) and of the seed part
(the pulp, MCP) of MC were prepared according to a modifi-
cation of a previously described method.22 Briefly, the MCF
and MCP (130 mg) were extracted using methanol at a 1 : 10
ratio. Homogenization was performed in a blender using
1-minute bursts at the highest speed for 12 minutes. The
homogenized extract was filtered through cheesecloth. A rotary
evaporator was used to remove most of the methanol, and any
remaining methanol evaporated using a water bath at 100 °C.
Charantin was provided by Xi’an Day Natural Technology
(Xi’an City, China). Bacterial endotoxins were removed from
the extracts and charantin using detoxi-gel endotoxin-remov-
ing gel columns (Thermo Scientific, Rockford, USA) and the
endotoxins quantified were below the detection limit (<0.125
EU mL−1) as measured by the E-toxate kit based on the
Limulus Amebocyte lysate assay.
2.2 Preparation of bovine serum albumin-derived advanced
glycation endproducts (BSA-AGEs)
BSA-AGEs were prepared and estimated as described pre-
viously.36 Briefly, bovine serum albumin (BSA) fraction V
(10 mg mL−1) was incubated at 37 °C for diﬀerent time periods
with 0.1 M methylglyoxal in 0.1 M sodium phosphate buﬀer
(pH 7.4) containing 3 mM sodium azide. Controls were incu-
bated under the same conditions without addition of sugars
or extracts. All incubations were carried out in triplicate. After
incubation, un-reacted sugars were removed by exhaustive
dialysis against distilled water for 2 days at 4 °C. BSA-AGE for-
mation was assessed using a fluorescence spectrophotometer
(Luminescence spectrometer model LS 30, PerkinElmer LAS
Ltd, Buckinghamshire, UK) with excitation at 350 nm and
emission at 420 nm. The endotoxin content of all protein solu-
tions were below the detection limit (<0.125 EU ml−1). Protein
concentrations were determined using a Bradford-based assay
with BSA as a standard.
2.3 Culture of bovine aortic endothelial cells
Tissue for primary cultures of bovine aortic endothelial cells
(BAEC) was obtained from the Manchester slaughterhouse and
cells isolated and characterized as described previously.37 The
cells were cultured in complete medium composed of 15%
fetal bovine serum (FBS) in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 2 mM L-glutamine, 100
IU mL−1 penicillin and 100 μg mL−1 streptomycin and seeded
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in tissue culture T-25 flasks coated with 0.1% gelatin. The
culture flasks were maintained at 37 °C in a humidified atmo-
sphere of 95% air and 5% CO2. Every 2–3 days, on reaching
confluence, the cells were passaged using enzymatic digestion
with 0.05% trypsin/0.02% ethylene-diamine-tetra-acetic acid
(EDTA) and split at a ratio of 1 : 2. Throughout the study, the
cells used were between passages 4 and 12.
2.4 Cell proliferation assay
BAEC (2.5 × 104 mL−1) in 1 mL of complete medium per well
were seeded into 24-well plates (Nunc™, Fisher Scientific,
Loughborough, UK). The cells were incubated for 4 hours,
allowing them to adhere to the bottom of the wells. The com-
plete medium was discarded, and the cells washed twice with
sterile phosphate-buﬀered saline (PBS). Fresh media sup-
plemented with 2.5% FBS, defined as serum-poor medium
(SPM), was added to each well. Extracts and charantin (10, 50
or 75 μg mL−1) were added to the wells and incubated for
72 hours. Untreated cells cultured in SPM and cells treated
with the pro-angiogenic growth factor FGF-2 (25 ng mL−1) were
used as negative and positive controls, respectively. In separate
experiments, BSA-AGEs (250 μg mL−1) were added to the wells
with or without extracts and charantin (10 μg mL−1). After
incubation for 72 hours, the cells were washed three times
with PBS and detached via incubation for 5 minutes in 250 μL
of 0.05% trypsin/0.02% EDTA. Each cell suspension was
diluted in 10 mL of isotonic solution prior to counting using a
Beckman-Coulter counter (Buckinghamshire, UK). Each experi-
ment was carried out in triplicate and repeated three times
independently. Cell viability was assessed using trypan blue
exclusion method, which stains dead cells while viable cells
exclude the dye. The percentage cell viability was obtained
using an automated cell counter TC10 (Bio-Rad Laboratories)
and determined according to the following formula:
% viability = (viable unstained cells)/(viable unstained cells +
dead stained cells) × 100.
2.5 Cell migration – wound healing assay
A sterile Thermanox® plastic coverslips (Nunc™) was placed
into each well of a 24-well plate. BAEC (6 × 104 mL−1) in 1 mL
of complete medium were seeded onto each coverslip. After
48 hours of incubation (pre-confluence), the complete
medium was replaced with SPM to reduce cell growth, and the
cells incubated for a further 24 hours. The cell monolayer
attached to the coverslip was washed twice with sterile PBS
and then wounded on each side of the central area with a
sterile razor blade to produce straight-edged cuts. The
wounded cell monolayer was washed three times with sterile
PBS to remove cellular debris and dislodged cells, and then
placed in a new 24-well plate containing fresh SPM. Various
concentrations of extracts and charantin (10, 50 or 75 μg mL−1)
were added to the wells and incubated for 24 hours. Untreated
cells in SPM and cells treated with FGF-2 (25 ng mL−1) were
used as negative and positive controls, respectively. In separate
experiments, BSA-AGEs (250 μg mL−1) were added to the wells
with or without extracts or charantin (10 μg mL−1). After incu-
bating for 24 hours, the coverslips were rinsed three times
with PBS, fixed in 100% ethanol for 5 minutes, and allowed to
air-dry. The cells were stained with methylene blue for
5 minutes and excess stain removed with distilled water.
Photomicrographs (40× magnification) were taken of 5 ran-
domly selected areas with straight wound edges on each cover-
slip using a Zeiss phase-contrast microscopy equipped with a
digital camera. Migration of cells in each field of view was
quantified by counting the migrated cells and by measuring
their distance from the wound edge using Image J software
(http://rsbweb.nih.gov/ij/indix.html). Each experiment was
carried out in triplicate, and repeated three times
independently.
2.6 Matrigel™ tube formation assay
BAEC (1 × 106 per 32 μL) were mixed with various concen-
trations of extracts and charantin (10, 50 or 75 μg mL−1) and
then in equal volume with growth factor-reduced Matrigel™
(Becton Dickinson, Oxford, UK). BSA-AGEs (250 μg mL−1) were
also tested with or without extracts or charantin (10 μg mL−1).
Each mixture was deposited equally under a spot shape into
two wells of a 48-well plate (Nunc™) per experimental con-
dition. Untreated cells in SPM and cells treated with FGF-2 (25
ng mL−1) were used as negative and positive controls, respect-
ively. Each condition was tested in duplicate. After polymeriz-
ation of the gel for 1 hour at 37 °C, each spot containing the
cells embedded in Matrigel™ was bathed in 500 µL of com-
plete medium. After incubation for 24 hours, some cells had
migrated and aligned surrounding an enclosed area. Cells
were fixed with 4% paraformaldehyde for 15 minutes and the
enclosed areas, used for quantification of tubulogenesis,38
were counted in 5 random fields using phase-contrast
microscopy (40× magnification).
2.7 Western blot analysis
BAEC (3 × 105 mL−1) in 1 mL of complete medium per well
were seeded into 24-well plates. After incubation for 24 hours
(pre-confluence), the medium was discarded, and cells washed
three times with PBS. Fresh SPM was added to each well for an
additional 24 hours of incubation. Various concentrations of
extracts and charantin (10, 50 or 75 μg mL−1) were added to
the wells and incubated for 10 minutes. BSA-AGEs (250
μg mL−1) were also tested with or without extracts and charan-
tin (10 μg mL−1). Untreated cells in SPM and cells treated with
FGF-2 (25 ng mL−1) were used as negative and positive con-
trols, respectively. Each condition was assayed in triplicate.
Immediately after incubation, medium was discarded, and the
cells were rinsed twice with cold PBS. After rinsing, intracellu-
lar proteins were extracted by lysing the cells with 100 µL per
well of ice-cold radioimmunoprecipitation (RIPA) buﬀer (pH
7.5) containing 25 mM Tris-HCl, 150 mM NaCl, 0.5% sodium
deoxycholate, 0.5% SDS, 1 mM EDTA, 1 mM sodium orthova-
nadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1%
Triton X-100 and 1 µM leupeptin. Cell lysates were centrifuged
for 30 minutes at 20 000g at 4 °C to remove any debris. The
protein concentration in each sample was determined using a
Paper Food & Function
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Bio-Rad protein assay. The volume of each sample containing
20 μg of protein was combined with an equal volume of 2×
sample buﬀer in Eppendorf tubes, mixed, and then placed in
boiling water for 15 minutes. The samples were separated
along with pre-stained molecular weight markers using
sodium dodecyl sulfate – polyacrylamide gel electrophoresis
(SDS-PAGE) on 12% acrylamide gels. The proteins were trans-
ferred to nitrocellulose membranes (1 hour) and the mem-
branes were blocked for 1 hour at room temperature in Tris-
buﬀered saline (TBS)-Tween (pH 7.4) containing 1% BSA. The
membranes were stained overnight at 4 °C on a rotating plat-
form with the following primary antibodies diluted in a block-
ing buﬀer: a mouse monoclonal antibody to phospho-extra-
cellular signal-regulated kinase (p-ERK1/2, Tyr204 of ERK1,
1 : 1000 dilution) and a rabbit polyclonal antibody to total
ERK1/2 (t-ERK1/2, 1 : 1000 dilution), both purchased from
Santa Cruz Biotechnology (Heidelberg, Germany). After
washing five times for 10 minutes in TBS-Tween at room temp-
erature, the membranes were stained with either horseradish
peroxidase rabbit anti-mouse or goat anti-rabbit secondary
antibodies diluted in TBS-Tween containing 5% non-fat milk
(1 : 1000 dilution) for 1 hour at room temperature with con-
tinuous mixing. After 5 additional washes in TBS-Tween, pro-
teins were visualized using the ECL chemiluminescent detec-
tion reagent (Amersham Biosciences, Buckinghamshire, UK)
and analyzed using GeneSnap software with Gene tool image
analyzer (Syngene, Cambridge, UK).
2.8 RAGE neutralization
To investigate whether the extracts and charantin act through
RAGE to induce angiogenic signaling via ERK1/2 phosphoryl-
ation and tube formation, the cells were treated with anti-
RAGE antibody to neutralize the RAGE receptors. Briefly, BAEC
in complete medium were seeded in wells of a 24-well plate
according to the western blotting protocol above. The medium
was replaced with SPM, and then 20 µg mL−1 of mouse mono-
clonal anti-RAGE [E-1] antibody (Santa Cruz Biotechnology) or
20 µg mL−1 of isotype control (IgG1). After incubation for
2 hours, cells were treated with extracts or BSA-AGEs (10
µg mL−1) for 10 minutes at 37 °C followed by protein extraction
for p-ERK1/2 protein detection using western blotting. The
cells were also subjected to the tube formation assay described
above with the diﬀerence that the cells were initially scraped to
maintain the intact RAGE structure. Anti-RAGE antibody or
IgG1 was added to the cold Eppendorf tube containing cells
for 1 hour on ice before the addition of extracts or charantin
(10 µg mL−1) and growth factor-reduced Matrigel™. Each con-
dition was tested in triplicate and each experiment repeated
three times.
2.9 Statistical analysis
Statistical analysis was performed using Microsoft Oﬃce Excel
2007 and results expressed as mean ± SD. Statistical signifi-
cance was analyzed using Student’s t-test and p values ≤0.05
were considered significantly diﬀerent.
3 Results
3.1 Momordica charantia extracts are pro-angiogenic in vitro
The eﬀects of 72-hour incubation with the MCP, MCF extracts
and charantin at concentrations between 10 and 75 µg mL−1
on BAEC are shown in Fig. 1A. Compared to the untreated
cells considered as negative control, pro-angiogenic growth
factor FGF-2 was used as a positive control to confirm the
ability of the cells to respond: it induced a significant increase
in cell number (67%, p = 0.0252, Fig. 1A). The exposure of
BAEC to increasing concentrations of MC extracts or charantin
significantly enhanced cell proliferation in a dose-dependent
manner, with a peak of stimulation found at an intermediate
concentration (50 μg mL−1) of the extracts (Fig. 1A).
Specifically, 10, 50 and 75 μg mL−1 of MCP increased BAEC
proliferation by 76% (p = 0.024), 125% (p = 0.0259) and 83%
(p = 0.0281), respectively, relative to the negative control
(Fig. 1A). Similarly, the same concentrations of MCF increased
cell growth by 69% (10 μg mL−1, p = 0.0251), 117%
(50 μg mL−1, p = 0.0277) and 81% (75 μg mL−1, p = 0.0261),
compared to negative control. Charantin at the same con-
centrations increased BAEC proliferation by 43% (10 μg mL−1,
p = 0.0254), 103% (50 μg mL−1, p = 0.0273) and 50%
(75 μg mL−1, p = 0.0197) when compared with the negative
control (Fig. 1A).
Because cell migration is an essential step in angiogenesis,
it was also important to evaluate the eﬀects of MCP, MCF and
charantin on BAEC migration using an in vitro injury model
such as wound-healing assay (Fig. 1B). Compared with the
untreated cells, the negative control (Fig. 1Bi); FGF-2 (25
ng mL−1, Fig. 1Bii), used as a positive control, significantly
increased the cell migration distance by 26.5% (p = 0.0282)
and the number of migrated cells by 47% (p = 0.0284, Fig. 1B).
At 10 µg mL−1, MCP significantly increased BAEC migration to
a level similar to FGF-2: the migration distance was increased
by 27% (p = 0.0284) and the number of migrated cells was
increased by 43% (p = 0.0284) relative to the negative control
(Fig. 1Biii and Bvi). At 50 µg mL−1, MCP significantly increased
the distance of migration by approximately 15% (p < 0.05), and
the cell number increased by 33% (p = 0.0288). However, 75
μg mL−1 MCP did not aﬀect either the cell migration distance
or number (Fig. 1Bvi). Furthermore, MCF (Fig. 1Biv and Bvii)
and charantin (Fig. 1Bv and Bviii) enhanced the distance of
migration by 15% at all concentrations used. However, the
highest response to increase the number of migrated cells was
found at 50 μg mL−1 of MCF (45%, p = 0.0281) or charantin
(40%, p = 0.0286) as compared with the negative control
(Fig. 1B).
To evaluate the eﬀects of the MC extracts on the last step of
angiogenesis, endothelial cell diﬀerentiation was assessed by
the tube formation assay using a 3-D Matrigel™ culture.
Within 24 hours of incubation, the activated endothelial cells
migrated, aligned to form tubes organized in a capillary-like
network (Fig. 1C). Representative photomicrographs of the
tube formation in the untreated condition (Fig. 1Ci), or after
treatment with either FGF-2 (Fig. 1Cii), or 10 μg mL−1 of MCP
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(Fig. 1Ciii), MCF (Fig. 1Civ) and charantin (Fig. 1Cv) are
shown. Treatment with the positive control, FGF-2, stimulated
the cells to form a capillary-like network (Fig. 1Cii). A signifi-
cant increase of 42% (p = 0.048) in the network density was
observed in the FGF-2-treated cells compared with the negative
untreated control cells, which formed a few tube-like struc-
tures (Fig. 1C). Although no eﬀect was noticed at the lowest
concentration of MCP, in the presence of 50 and 75 μg mL−1
MCP, the tube formation significantly increased by 74% (p =
0.0093) and 41% (p = 0.046), respectively, compared with the
negative control (Fig. 1Cvi). All concentrations of MCF signifi-
cantly enhanced tube formation relative to the negative
control: 162% (p = 0.0082) at 10 μg mL−1, 197% (p = 0.0078) at
50 μg mL−1 and 182% (p = 0.0079) at 75 μg mL−1 (Fig. 1Cvi).
Charantin also significantly enhanced the endothelial tube for-
mation in a concentration-dependent manner (Fig. 1Cvi).
Specifically, 10, 50 and 75 μg mL−1 of charantin significantly
increased the number of enclosed areas by 57% (p = 0.049), by
149% (p = 0.0076) and 219% (p = 0.0079), respectively, com-
pared with the negative control (Fig. 1Cvi).
3.2 Momordica charantia extracts increase the
phosphorylation of angiogenic signaling protein ERK1/2
Because the activation of ERK1/2 is considered as the key step
of angiogenesis,17 phospho-ERK1/2 (p-ERK1/2) expression
levels in presence of the MC extracts and charantin were exam-
ined. To optimize the incubation time corresponding to the
maximal cell signaling induced by MC extracts at the concen-
trations showing similar eﬀects than FGF-2 (positive control),
western blotting was used to determine the levels of p-ERK1/2
expression in BAEC treated with 10 μg mL−1 MCP (MC extract
with strongest pro-mitogenic eﬀect) for 10 minutes and 1, 3 or
6 hours of incubation. After 10 minutes of incubation of the
cells with MCP, the phosphorylation of ERK1/2 was signifi-
cantly increased (5.0-fold, p < 0.01, Fig. 2) compared with the
basal level of p-ERK1/2 expressed in untreated (negative)
control cells. This eﬀect was similar to that of FGF-2 (Fig. 2).
The level of p-ERK1 slightly decreased at the 1-hour time
point, and had nearly disappeared after 6 hours (Fig. 2).
Fig. 3 shows a representative western blot using BAEC lysate
proteins after a 10-minute treatment of the cells with diﬀerent
concentrations (10, 50 or 75 µg mL−1) of the MC extracts or
charantin or the positive control, FGF-2. As expected, treatment
with FGF-2 significantly induced the p-ERK1/2: a 5.5-fold (p <
0.001) increase in p-ERK2 and a 1.9-fold (p < 0.01) increase in
p-ERK1 were observed compared with the basal levels of
p-ERK1/2 in untreated control cells (Fig. 3). Treatment of the
cells with MCP (Fig. 3A), MCF (Fig. 3B) and charantin (Fig. 3C)
significantly (p < 0.01) increased the levels of p-ERK1/2 in a
dose-dependent manner, with the highest response found at
50 μg mL−1 of MCP (4.7-fold increase of p-ERK2 expression,
1.8-fold increase of p-ERK1 expression; Fig. 3A), MCF (4.5-fold
increase p-ERK2, 1.8-fold p-ERK1 expression; Fig. 3B) or char-
antin (3.79-fold of p-ERK2 expression, 1.23-fold p-ERK1
expression; Fig. 3C), compared with the negative control.
Fig. 1 Eﬀects of Momordica charantia extracts on proliferation,
migration and tube formation of BAEC. (A) Untreated BAEC (control) or
those treated either with 25 ng mL−1 FGF-2, or various concentrations of
MCP, MCF or charantin for 72 hours of incubation. The bar graph shows
the stimulatory eﬀects of MCP, MCF and charantin. The data are pre-
sented as the mean ± SD (n = 3). (B) Representative photomicrographs
(40× magniﬁcation) show the BAEC measured from the wound edge
(indicated by dashed lines) after incubation for 24 hours for untreated
cells (i), or those treated with FGF-2 (ii) or 10 μg mL−1 of MCP (iii), MCF
(iv) or charantin (v). The bar graphs show the number of migrated cells
(dark bars) and the distance of migration (clear bars) of the BAEC under
these conditions including the three concentrations of MCP (vi), MCF
(vii) and charantin (viii). The data are presented as the mean ± SD (n = 3).
(C) Representative photomicrographs (40× magniﬁcation) showing the
BAEC tube formation after a 24-hour incubation in untreated cells (i),
and those treated with FGF-2 (ii) or 10 μg mL−1 of MCP (iii), MCF (iv) or
charantin (v). The enclosed areas (an example as indicated by the arrow)
were counted as a parameter for quantiﬁcation of tubulogenesis. The
bar graphs (vi) show the eﬀects of MCP, MCF extracts and charantin
respectively on tube formation. The data are presented as the mean ±
SD (n = 3). (*) and (**) indicate statistically signiﬁcant diﬀerences (p <
0.05 and p < 0.01 respectively) from the control.
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3.3 Biphasic dose-dependent eﬀects of BSA-AGEs on p-ERK1/
2 levels
To determine the eﬀects of diﬀerent concentrations of
BSA-AGEs on phosphorylation of key angiogenic signaling
molecules ERK1/2, BAEC were stimulated with BSA-AGEs (25,
50, 100 or 250 μg mL−1) for 10 minutes. At these various con-
centrations, BSA-AGEs modulated ERK1/2 phosphorylation in
a dose-dependent manner and showed biphasic eﬀects.
Indeed, at 50–100 μg mL−1 of BSA-AGEs, a significant (p <
0.01) increase in the phosphorylation of ERK1/2 was observed
(around 4.0-fold increase of p-ERK1, around 4.5-fold increase
of p-ERK2), while 250 μg mL−1 BSA-AGEs inhibited ERK1/2
phosphorylation, compared with the level of p-ERK1/2 in
untreated control cells (Fig. 4). At the lowest concentration
(25 μg mL−1), BSA-AGEs did not change ERK1/2 phosphoryl-
ation level as compared with the level of p-ERK1/2 detected in
untreated control cells (Fig. 4).
3.4 Momordica charantia extracts reduce anti-angiogenic
eﬀects of BSA-AGEs
MC extracts have beneficial eﬀects on delayed wound-healing
observed in diabetic patients in vivo. To investigate the mole-
cular mechanisms involved, the eﬀects of MC extracts and
charantin were tested using the in vitro angiogenesis assays.
The high concentration of BSA-AGEs (250 μg mL−1) inhibited
BAEC proliferation by 70% relative to the negative control, the
untreated cell population (Fig. 5A), but native BSA had no
eﬀect (data not shown). The addition of 10 μg mL−1 of the
MCP significantly reduced the inhibitory eﬀect of BSA-AGEs
on the proliferation of BAEC by 1.9-fold (p = 0.0068), compared
with the negative control. Similarly, the MCF extract or charan-
tin reduced the inhibitory eﬀect of BSA-AGEs by 1.7-fold (p =
0.009) (Fig. 5A). There were no eﬀects of any of the extracts,
BSA-AGEs or native BSA on the cell viability (data not shown).
To determine whether the MC extracts altered the eﬀects of a
high concentration of BSA-AGEs (250 μg mL−1) on the
migration of BAEC (Fig. 5B), representative photomicrographs
of the migration of untreated cells (Fig. 5Bi) or cells treated
with FGF-2 (Fig. 5Bii), BSA-AGEs (Fig. 5Biii) or BSA-AGEs com-
bined with MCP (Fig. 5Biv), MCF (Fig. 5Bv) or charantin
(Fig. 5Bvi) were evaluated. Treatment of the cells with the high
concentration of BSA-AGEs decreased the cell migration dis-
tance by 50% (p = 0.028) and the number of migrated cells by
40% (p = 0.026), compared to the negative control. Native BSA
at 250 μg mL−1 did not aﬀect cell migration (data not shown).
The addition of MCP and MCF extracts reduced the inhibitory
eﬀect of the BSA-AGEs on BAEC migration distance by approxi-
Fig. 2 Time course of angiogenic signaling p-ERK1/2 levels in BAEC
treated with 10 μg mL−1 of the MCP extract. (A) Representative western
blot analysis showing the eﬀect of FGF-2 (positive control, 10 minutes
incubation) and of 10 μg mL−1 MCP extract on the p-ERK1/2 levels in
BAEC after 10 minutes, 1 hour, 3 hours and 6 hours of incubation as
compared with the untreated cells (control). Total ERK1/2 expression
was used as a loading control. (B) Bar graph showing the densitometric
quantiﬁcation of the bands expressed as values relative to total-ERK1/2
levels and calculated as the ratio to the levels in the control cultures.
The results are presented as the mean ± SD (n = 3). (*), (**) and (***)
signify statistically signiﬁcant diﬀerences (p < 0.05, p < 0.01 and p <
0.001, respectively) from the control.
Fig. 3 Momordica charantia extracts increase p-ERK1/2 levels in cul-
tured BAEC. Representative western blots showing the levels of p-ERK1/
2 induced by 10–75 µg mL−1 of MCP (A1) or MCF (B1) extracts and char-
antin (C1) after a 10-minute incubation. The bar graphs show the
p-ERK1/2 expression levels induced by MCP (A2), MCF (B2) extracts and
charantin (C2). The data show the densitometric quantiﬁcation of the
bands expressed as values relative to total-ERK1/2 levels and calculated
as the ratio to the levels in the control cultures. The results are pre-
sented as the mean ± SD (n = 3). (*), (**) and (***) signify statistically sig-
niﬁcant diﬀerences (p < 0.05, p < 0.01 and p < 0.001, respectively) from
the control.
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mately 1.5-fold (p < 0.05) and the number of migrated cells by
approximately 1.6-fold (p < 0.05), compared to the cells treated
with BSA-AGEs (Fig. 5Bvii). Charantin also reduced the inhibi-
tory eﬀect of BSA-AGEs on the migration distance by 1.28-fold
(p = 0.035) and the number of migrated cells by approximately
1.29-fold (p = 0.025) (Fig. 5Bvii).
Representative photomicrographs of the tube formation in
cells treated with 250 μg mL−1 BSA-AGEs (Fig. 5Ci) or
BSA-AGEs combined with 10 μg mL−1 MCP (Fig. 5Cii), MCF
(Fig. 5Ciii) or charantin (Fig. 5Civ) are shown. The high con-
centration of BSA-AGEs significantly decreased the tube for-
mation by 0.67-fold (p = 0.014; Fig. 5Cv) as compared with the
control, while native BSA had no eﬀect (data not shown). The
addition of the MC extracts (MCP and MCF) to the high con-
centration of BSA-AGEs not only suppressed the inhibitory
eﬀect of BSA-AGEs on BAEC tube formation but actually sig-
nificantly increased the tube formation by 2.7-fold (p < 0.01),
compared to the BSA-AGEs-treated cells (Fig. 5Cv). The
addition of charantin to the high concentration of BSA-AGEs
also reduced the inhibitory eﬀect of the BSA-AGEs on BAEC
tube formation and slightly increased the tubulogenesis
process by 1.5-fold (p = 0.013) as compared to the BSA-AGEs
treated cells (Fig. 5Cv).
3.5 Momordica charantia extracts exert endothelial
angiogenic functions through RAGE
We next wondered whether MC extracts and charantin acted
through RAGE as AGEs do and thus, explain how MC extracts
interfere in the angiogenic eﬀects of AGEs. This hypothesis
was verified based on the induced phosphorylation of angio-
genic signaling protein ERK1/2 and on tube formation. The
receptor was neutralized using an anti-RAGE antibody at a con-
Fig. 4 Biphasic eﬀects of BSA-AGEs on p-ERK1/2 levels in a dose-
dependent manner. (A) Representative western blot analysis showing the
levels of p-ERK1/2 after a 10-minute incubation with a range of concen-
trations of BSA-AGEs. (B) The bar graph shows the densitometric
quantiﬁcation of the bands expressed as values relative to total-ERK1/2
levels and calculated as the ratio to the levels in the control cultures.
The results are presented as the mean ± SD (n = 3). (*), (**) and (***)
signify statistically signiﬁcant diﬀerences (p < 0.05, p < 0.01 and p <
0.001, respectively) from the control.
Fig. 5 Eﬀects of Momordica charantia extracts on proliferation,
migration and tube formation of BAEC exposed to high concentrations
of BSA-AGEs. (A) Untreated BAEC (control) or those treated for a
72-hour incubation either with 25 ng mL−1 FGF-2, 250 μg mL−1
BSA-AGEs alone or BSA-AGEs combined with 10 µg mL−1 of MCP, MCF
or charantin as shown. The bar graph shows the eﬀects of MCP, MCF
or charantin on the inhibition of cell proliferation induced by the
BSA-AGEs. The data are presented as mean ± SD (n = 3). (B)
Representative photomicrographs (40× magniﬁcation) showing the
BAEC measured from the wound edge (indicated by dashed lines) after a
24 hours incubation for the untreated cells (i), or treated either with
FGF-2 (ii) or 250 μg mL−1 BSA-AGEs alone (iii) or combined with 10 μg
mL−1 of MCP (iv), MCF (v) or charantin (vi). The bar graphs (vii) show the
number of migrated cells (dark bars) and the distance of migration (clear
bars) of the BAEC under these conditions. The data are presented as the
mean ± SD (n = 3). (C) Representative photomicrographs (40× magniﬁ-
cation) showing the BAEC tube formation in cells treated with 250 μg
mL−1 BSA-AGEs alone (i) or combined with 10 μg mL−1 of MCP (ii), MCF
(iii) or charantin (iv) after 24 hours of incubation. The closed areas were
counted for quantiﬁcation of tubulogenesis. The bar graph (v) shows the
eﬀects of MCP, MCF extracts and charantin on tube formation. The data
are presented as the mean ± SD (n = 3). (*) and (**) indicate statistically
signiﬁcant diﬀerences (p < 0.05 and p < 0.01, respectively) from the
control.
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centration previously shown to inhibit AGE-induced cell func-
tions following RAGE neutralization,35 and the phosphoryl-
ation of ERK1/2 was evaluated in the presence of BSA-AGEs,
MCF, MCP extracts or charantin. The isotype control IgG1 did
not aﬀect ERK1/2 phosphorylation induced by 50 μg mL−1
BSA-AGEs, compared with the basal expression level of
p-ERK1/2 in untreated control cells (Fig. 6A). However, pre-
treatment with the neutralizing RAGE antibody prevented the
increase in ERK1/2 phosphorylation induced by 50 μg mL−1
BSA-AGEs (Fig. 6A). Neutralization of RAGE with the anti-RAGE
antibody strongly inhibited the ERK1/2 phosphorylation
induced by MC extracts and charantin, while pre-treatment
with IgG1 did not change the increases in p-ERK1/2 levels
induced by MC extracts and charantin, compared with the
control (Fig. 6A).
Next, the cells were treated with an anti-RAGE antibody or
an IgG1 control, and tubulogenesis was assessed in the pres-
ence of BSA-AGEs or MCF. The addition of MC extracts and
charantin to IgG1-pretreated cells surprisingly induced a sig-
nificant increase in endothelial tube formation (Fig. 6B) as
compared with the untreated control cells. However, the
addition of either MCF extract (previously shown to have the
strongest pro-angiogenic eﬀects) or 10 μg mL−1 BSA-AGEs to
anti-RAGE antibody-pretreated cells suppressed their pro-
angiogenic eﬀects as compared with the untreated control
cells (Fig. 6B).
4 Discussion
Momordica charantia is a popular vegetable in Asia for its anti-
oxidant, hypoglycemic and therefore anti-diabetic properties,
which were recognized more than 600 years ago.23,39 Indeed,
administration of MC extracts to diabetic rats over 30 days not
only reduced hyperglycemia but also reduced lipid peroxi-
dation and increased intracellular production of antioxidants
such as superoxide dismutase, catalase and glutathione in
heart tissue of diabetic rats.25 Furthermore, MC extracts pro-
tected cultured human neuroblastoma cells against intracellu-
lar oxidative stress and improved their viability and reduced
apoptosis.40 As a cheap and potential medicinal plant-based
natural therapeutic food, a growing body of evidence supports
the beneficial eﬀects of MC extracts on impaired wound-
healing in diabetic animal models.32,34 However, the mole-
cular mechanisms underlying the pro-angiogenic eﬀects of
MC extracts and its ability to protect against AGEs, which are
the main cause of diabetic vascular complications including
impairment of wound-healing, remained unclear. Here, we
have demonstrated that two standardized methanolic extracts
of MC (MCP and MCF) and charantin had pro-angiogenic
eﬀects in vitro. These eﬀects were mediated by interactions
with the main receptor for AGEs (RAGE), through which these
extracts may reduce the anti-angiogenic eﬀects of a high con-
centration of AGEs. This study helps improve our understand-
ing of the angiogenic molecular mechanisms underlying use
of MC extracts to promote healing in the diabetic wound.
Fig. 6 Eﬀect of RAGE neutralization on the modulation of p-ERK1/2
levels and tube formation by the MC extracts and charantin. (A): (A1)
Representative western blot analysis showing the levels of p-ERK1/2
induced by either 50 μg mL−1 BSA-AGEs or 10 μg mL−1 MC extracts and
charantin in cells treated with the isotype control IgG1 and anti-RAGE
antibody. (A2) The bar graph shows the densitometric quantiﬁcation of
the bands corresponding to p-ERK1/2 levels expressed as values relative
to total-ERK1/2 levels and calculated as the ratio to the levels in the
control cultures. The data are presented as the mean ± SD (n = 3). (B1)
Representative photomicrographs (40× magniﬁcation) showing the
BAEC tube formation in untreated cells and pre-treated cells with IgG1
and anti-RAGE antibody then cultured in the presence or absence of
either 250 μg mL−1 BSA-AGEs or 10 μg mL−1 of MCF for 24 hours of
incubation. The closed areas were counted for quantiﬁcation of tubulo-
genesis. (B2) The bar graph shows the loss of MCF-induced tube for-
mation after treatment with a RAGE neutralization antibody, compared
with untreated cells (control) and those treated with the isotype control
IgG1. The data are presented as mean ± SD (n = 3). (*), (**) and (***)
signify statistically signiﬁcant diﬀerences (p < 0.05, p < 0.01 and p <
0.001, respectively) from the control.
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This study used high concentrations of methylglyoxal to
prepare BSA-AGEs in vitro. This enabled us to produce AGEs in
a short time period and reduce the risk of bacterial contami-
nation of protein samples. Such model AGEs have been used
previously to study cellular functions.36 To validate our in vitro
angiogenesis assays, FGF-2 was used as a positive control. This
compound is considered as one of the strongest pro-angio-
genic growth factor, inducing here a concomitant enhance-
ment of cell proliferation, migration and tube formation. Our
results indicate that all of the MC extracts (MCF, MCP and
charantin) increased endothelial cell proliferation in a dose-
dependent manner. The lowest and the highest concentrations
of the MC extracts (i.e. 10 and 75 μg mL−1) stimulated cell pro-
liferation to a level similar to that induced by FGF-2. However,
the intermediate concentration of MC extracts (i.e., 50
μg mL−1) stimulated proliferation to a greater level than that
induced by FGF-2, indicating the maximal activation of the sig-
naling pathways. This increase of cell proliferation with MC
extract concentration in a bell-shaped curve manner suggests a
receptor dependent-mechanism, whose optimal stimulation
(peak) might correspond to the optimal oligomerization of the
receptor.15 Among the bioactive phytochemical components
and proteins previously mentioned, MC extracts contain
insulin-like proteins which may stimulate endothelial cell pro-
liferation by acting as an insulin-like growth factor (a pro-
angiogenic growth factor) bound to two dimers of insulin
receptors followed by the activation of the receptor tyrosine
kinase.20,41 In addition, a recent study has reported that
topical insulin accelerates the skin wound-healing in diabetic
rats.42 To understand the molecular mechanism involved in
the pro-mitogenic eﬀect of charantin it is important to know
that charantin is mainly composed of the combination of
sterol and glucose metabolites. Glucose is an essential and
vital metabolite for cell function and its facilitated transport
through the hexose transporter (e.g. GLUT1) is accompanied
by a linear cell response but cannot explain the bell-shaped
curve as previously described, which suggests a receptor-
dependent mechanism.41,43 Therefore, charantin, which is
also considered as a glycated phytochemical compound,
could be recognized by a receptor for AGEs such as RAGE.
Altogether, these findings suggest that MC extracts stimulated
endothelial cell proliferation through receptor-dependent
mechanisms, which remain to be identified.
In contrast to their similar pro-mitogenic eﬀects on cell pro-
liferation, we showed that the MC extracts and charantin acted
diﬀerently on the increase in the number of migrated cells
using the wound-healing assay. However, MC extracts and
charantin enhanced the distance of migration with an eﬃcacy
similar to that of FGF-2. MCP extract tested at the highest con-
centration (i.e., 75 μg mL−1) actually inhibited the number of
migrated cells, while MCF extract and charantin increased the
migrated cell number in a dose-dependent manner with a
peak of stimulation at 50 μg mL−1, close to the level induced
by FGF-2. These methanolic extracts of MCF and MCP contain
ascorbigen, a bound form of ascorbic acid, low doses of which
have been shown to have pro-angiogenic eﬀects20,44 whereas
high doses have anti-angiogenic eﬀects.45 An assessment of
the content of ascorbigens from each MC extract might explain
their diﬀerential eﬀects on migrated cell number. Concerning
charantin eﬀect, the presence of sterol has been reported to
induce changes in the contents of membrane cholesterol and
alters the micro-viscosity of the plasma membrane, which in
turn can regulate endothelial cell migration.46
Regarding tubulogenesis process, which corresponds to the
last step of angiogenesis, both MCP and MCF extracts
enhanced tube formation in a dose-dependent manner with a
peak of stimulation at 50 μg mL−1. At this concentration, MCP
showed a stimulatory eﬀect similar to that of FGF-2, but the
eﬀect of the MCF extract was almost twice that of FGF-2. This
finding suggests that MCF extracts might contain more
insulin-like proteins or other stimulating agents than the MCP
extracts. In contrast to the MCP and MCF extracts, charantin
increased tube formation with its increasing concentrations:
the stimulatory eﬀect of the lowest concentration was similar
to that of FGF-2, but was nearly twice that of FGF-2 eﬀect at
the highest concentration. Charantin thus eﬀectively stimu-
lated endothelial tube formation, but its eﬀect was not as great
as that induced by the MCF extract. With regards to the char-
antin eﬀect, the presence of sterol might be involved in the
promotion of tubulogenesis through the activation of sterol
regulatory element-binding proteins (SREBP), previously
demonstrated to play a key role in angiogenesis.47 Thus, an
assessment of the SREBP activation might reveal the involve-
ment of SREBP in charantin-induced tube formation.
The maximal increase in the p-ERK1/2 expression for the
three MC extracts occurred at 50 μg mL−1, at the concentration
that induced the maximal stimulation of cell proliferation,
migration and tube formation. However, FGF-2 had a greater
eﬀect on the levels of p-ERK1/2 than the MC extracts, but its
eﬀects on the pro-angiogenic responses were similar or
smaller. These results suggest that p-ERK1/2 may not be the
primary target signaling protein involved in the signal trans-
duction aﬀected by MC extracts and charantin. The expression
of a panel of activated phospho-protein expressions should be
screened to identify the primary phospho-proteins aﬀected by
MC extracts and charantin.
In agreement with previous studies, we showed that metha-
nolic MC extracts and charantin have beneficial eﬀects on
AGE-inhibited angiogenesis, which was used as an in vitro
model mimicking the impaired wound-healing in diabetic
patients. Here, we confirmed that a high dose of BSA-AGEs
(250 μg mL−1) inhibit angiogenesis, as reported previously.48
These authors showed that 500 μg mL−1 BSA-AGEs inhibit
retinal vascular cell proliferation, whereas at low doses of
BSA-AGEs (62.5–100 μg mL−1) induce these angiogenic pro-
cesses.13,48 In addition, high concentrations of BSA-AGEs have
been reported to impair cell migration, adhesion and secretion
of vasoactive substances by late bone marrow-derived endo-
thelial progenitor cells, which are important in neovasculariza-
tion.29 Therefore, in diabetic patients, the local accumulation
of AGEs in the vessel wall or within the tissue may impair the
neovascularization process by interfering with the cell-matrix
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interactions. The biological eﬀects of AGEs are mainly
mediated through interactions with the AGE-specific receptor,
RAGE. RAGE is a multi-ligand signal transduction receptor
and its protein expression is induced by AGEs and is over-
expressed in diabetic conditions.49 Shoji and colleagues50 per-
formed an in vivo study that compared the responses of non-
diabetic mice to those of RAGE−/− mice. The study demon-
strated that adenovirus-mediated over-expression of endogen-
ous secreted RAGE, a decoy receptor for RAGE, corrects the
diabetes-associated impairment of angiogenic responses
in vivo. These findings support the suggestion that RAGE is
involved in impairment of angiogenesis as seen in diabetic
wound-healing whereas blockade of RAGE receptors may have
a potential therapeutic eﬀect. This study also demonstrated
that the neutralization of the RAGE receptor utilizing a specific
monoclonal antibody suppressed the phosphorylation of
ERK1/2, the activation of the key angiogenic signaling protein,
induced by all of the MC extracts including charantin and
inhibited the tube formation induced by MCF extract (selected
for its strongest tubulogenic eﬀect). These important findings
highlighted the presence of biologically active proteins and
phytochemicals in MC extracts mediating RAGE activation,
which remain to be clarified. Furthermore, the MC extracts
could act not only by binding to RAGE but also by binding to
the BSA-AGEs thus preventing their interaction with RAGE.
Here we also observed that MC extracts combined with high
AGE concentration not only reduced anti-angiogenic eﬀects of
AGEs but also reversed tubulogenesis process. Beyond their
pro-angiogenic eﬀects, MC extracts have been recently identi-
fied from a clinical study in diabetic patients as potent natural
compounds for the prevention of AGE formation, which was
demonstrated to restore angiogenesis.39 An in vivo study
demonstrated that aqueous extracts of MC improve wound-
healing in albinos rats; this beneficial eﬀect was linked to
increased production of extracellular matrix proteins and
hydroxyproline, a constituent of collagen that plays a key role
in collagen stability.31 Importantly, increased production of
collagen facilitates endothelial tube formation. This finding is
consistent with the increased tube formation induced by the
MC extracts even when added to high concentration of
BSA-AGEs. In addition to laminin, the type I collagen fibrils
are a major component of Matrigel™, and this material has
been reported to promote rapid vascular tube formation.51 The
hypothesis that the MC extracts caused an increase in protein
synthesis in the BAEC remains to be investigated. The discre-
pancies between endothelial cell proliferation/migration and
tube formation suggest that the MC extracts counteracted the
anti-angiogenic eﬀects of the AGEs by distinct mechanisms,
one of which may be receptor-dependent through binding
competitiveness between MC extracts and AGEs high concen-
tration to RAGE receptor.
In conclusion, our results of this in vitro study show that
MC extracts and charantin exert strong pro-angiogenic eﬀects.
These observations support the beneficial eﬀects of topical
MC extracts on wound-healing. Although the MC extracts and
charantin contain diﬀerent biologically active constituents, we
found that RAGE was involved in the stimulation of angio-
genesis, including cell signaling and tubulogenesis, by these
extracts. Thus, further study of the structure–function relation-
ships of the MC extracts might facilitate the development of
new therapies to promote wound-healing using natural pro-
angiogenic compounds.
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AGEs Advanced glycation endproducts
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